What is Savient Pharmaceuticals Cyclically Adjusted Revenue per Share?
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Savient Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2013 was €0.068. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-05-14), Savient Pharmaceuticals's current stock price is €0.03. Savient Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2013 was €0.00. Savient Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .
Savient Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data
The historical data trend for Savient Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Savient Pharmaceuticals Cyclically Adjusted Revenue per Share Chart
|
Savient Pharmaceuticals Annual Data
|
|
Trend |
Dec03 |
Dec04 |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
Dec11 |
Dec12 |
| Cyclically Adjusted Revenue per Share |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Savient Pharmaceuticals Quarterly Data
|
|
Mar09 |
Jun09 |
Sep09 |
Dec09 |
Mar10 |
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Mar14 |
| Cyclically Adjusted Revenue per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Savient Pharmaceuticals's Cyclically Adjusted Revenue per Share
For the Biotechnology subindustry, Savient Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Savient Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Savient Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Savient Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Savient Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Savient Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2013 was:
| Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2013 (Change) | * | Current CPI (Sep. 2013) |
| = | 0.068 | / | 98.7900 | * | 98.7900 |
| = | 0.068 |
Current CPI (Sep. 2013) = 98.7900.
Savient Pharmaceuticals Quarterly Data
|
Revenue per Share |
CPI |
Adj_RevenuePerShare |
| 200312 |
0.535 |
77.758 |
0.680 |
| 200403 |
0.454 |
79.066 |
0.567 |
| 200406 |
0.242 |
80.037 |
0.299 |
| 200409 |
0.358 |
80.121 |
0.441 |
| 200412 |
0.441 |
80.290 |
0.543 |
| 200503 |
0.288 |
81.555 |
0.349 |
| 200506 |
0.306 |
82.062 |
0.368 |
| 200509 |
0.280 |
83.876 |
0.330 |
| 200512 |
0.312 |
83.032 |
0.371 |
| 200603 |
0.253 |
84.298 |
0.296 |
| 200606 |
0.304 |
85.606 |
0.351 |
| 200609 |
0.205 |
85.606 |
0.237 |
| 200612 |
0.122 |
85.142 |
0.142 |
| 200703 |
0.093 |
86.640 |
0.106 |
| 200706 |
0.044 |
87.906 |
0.049 |
| 200709 |
0.035 |
87.964 |
0.039 |
| 200712 |
0.025 |
88.616 |
0.028 |
| 200803 |
0.014 |
90.090 |
0.015 |
| 200806 |
0.004 |
92.320 |
0.004 |
| 200809 |
0.007 |
92.307 |
0.007 |
| 200812 |
0.015 |
88.697 |
0.017 |
| 200903 |
0.015 |
89.744 |
0.017 |
| 200906 |
0.008 |
91.003 |
0.009 |
| 200909 |
0.004 |
91.120 |
0.004 |
| 200912 |
0.009 |
91.111 |
0.010 |
| 201003 |
0.012 |
91.821 |
0.013 |
| 201006 |
0.012 |
91.962 |
0.013 |
| 201009 |
0.011 |
92.162 |
0.012 |
| 201012 |
0.010 |
92.474 |
0.011 |
| 201103 |
0.013 |
94.283 |
0.014 |
| 201106 |
0.020 |
95.235 |
0.021 |
| 201109 |
0.027 |
95.727 |
0.028 |
| 201112 |
0.040 |
95.213 |
0.042 |
| 201203 |
0.038 |
96.783 |
0.039 |
| 201206 |
0.052 |
96.819 |
0.053 |
| 201209 |
0.054 |
97.633 |
0.055 |
| 201212 |
0.053 |
96.871 |
0.054 |
| 201303 |
0.051 |
98.209 |
0.051 |
| 201306 |
0.070 |
98.518 |
0.070 |
| 201309 |
0.068 |
98.790 |
0.068 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Savient Pharmaceuticals (FRA:BY7) Business Description
Traded in Other Exchanges
N/A
Address
Savient Pharmaceuticals, Inc., was founded in 1980. It develops, manufactures and markets products through the application of genetic engineering and related biotechnologies. The Company, and its wholly-owned Subsidiaries, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. It completed a promotional launch of KRYSTEXXA in the United States during the first quarter of 2011 with its sales force commencing field promotion to health care providers on February 28, 2011. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company launched its authorized generic version of oxandrolone in December 2006 in response to the approval and launch of generic competition to Oxandrin. On January 1, 2012, KRYSTEXXA received a permanent J Code, which facilitates reimbursement to providers who treat patients suffering with RCG and who rely on Medicare and Medicaid. The manufacturing process for pegloticase, which is the drug substance of KRYSTEXXA, consists of the production through a recombinant process in which a genetically-engineered bacteria produces uricase, followed by its purification, PEGylation, further purification and formulation to produce the bulk pegloticase, which the company refers it as pegloticase drug substance. Pegloticase is aseptically filtered and filled into sterile, single dose vials to produce the KRYSTEXXA drug product. Its sales force targets rheumatologists and nephrologists with access to infusion centers and healthcare institutions, each of which treat adult patients suffering from RCG, as well as podiatrists who also treat patients with RCG. In March 2012, KRYSTEXXA was made available in the EU to healthcare professionals through a Named Patient Program. The Company sells its products to three drug wholesaler customers and various specialty distributors. Its research and development includes costs associated with the research and development of its KRYSTEXXA product prior to FDA approval and FDA-related post-marketing commitments for approved products (KRYSTEXXA post-approval). These costs mainly include pre-clinical and clinical studies and trials, personnel costs including compensation, consultants and contract research organizations, or CROs, quality control and assurance costs, regulatory costs and costs related to the development of commercial scale manufacturing capabilities for KRYSTEXXA, which also includes the costs of preparing Fujifilm to serve as its secondary source supplier of pegloticase drug substance for KRYSTEXXA in the United States. As of March 7, 2013, the company owned 14 issued U.S. patents and 154 issued foreign patents. It currently owns U.S. and several foreign registrations or applicat
Savient Pharmaceuticals (FRA:BY7) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:BY7 has been successfully added to your